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Rare families exist in which there appears to be a predisposition to
cutaneous melanoma (Clark et al, 1978; Newton, 1994). In some
families, there is an apparent susceptibility to other tumours,
particularly to pancreatic (Lynch and Fusaro, 1991) and other
gastrointestinal cancers (Bergman et al, 1990), but in most
families the susceptibility appears to be to melanoma alone. Early
linkage data suggestive of linkage to chromosome 1 (Bale et al,
1989; Goldstein et al, 1993) have not been substantiated (Gruis
et al, 1990; Nancarrow et al, 1992), but strong evidence of linkage
to chromosome 9 (Cannon-Albright et al, 1992; Nancarrow et al,
1993) was quickly followed by the identification of germline
mutations in the INK4A (CDKN2) gene (on chromosome 9p)
which codes for the p16 protein, in melanoma families
(Hussussian et al, 1994; Kamb et al, 1994). Mutations in this gene
have been identified in the germline of families world-wide
(Dracopoli and Fountain, 1996), mutations that co-segregate with
cases and for which abnormal CDK4 binding has been demon-
strated (Harland et al, 1997). The proportion of families with
mutations, however, remains moderate, at around 40% of families
with three or more cases overall. In our initial UK series, five of 12
families of this type, and one of 12 families with two cases of
melanoma had identifiable mutations in the INK4A gene (Harland
et al, 1997).
There is some evidence for linkage to chromosome 9 even in
families without identifiable INK4A mutations (Hussussian et al,
1994; Liu et al, 1997) so that there may be additional mutations yet
to be identified in the promoter region of the gene, or in other
linked genes. No significant contribution has been identified from
two candidate genes in this region, coding for the protein p15 and
p14ARF (Fitzgerald et al, 1996). There are, however, haplotype
data to suggest that there are likely to be other melanoma suscepti-
bility genes elsewhere (Goldstein et al, 1994; MacGeoch et al,
1994).
Zuo et al (1996) have identified one such gene. They reported
mutations in the gene that codes for the target protein of p16,
CDK4. Three families have now been reported world-wide in
which germline CDK4 mutations have been detected in melanoma
families (Zuo et al, 1996; Bressac-de-Paillerets et al, 1997). In
these families, single base pair substitutions were detected at the
same point in the p16-binding domain, residue 24 and, more
recently, mutations have been detected in a second domain also
important in binding to cyclin D1 (Coleman et al, 1997), strength-
ening considerably the significance of the p16–CDK4–RB
pathway in melanoma carcinogenesis. Several groups have now
looked at their melanoma families without identifiable INK4A
mutations and have failed to identify additional CDK4 mutations.
It is clear, therefore, that CDK4 mutations are rare (Harland et al,
1997) and that there are other melanoma susceptibility genes still
to identify.
p16 is a member of a family of CDK inhibitors, the INK4
family. The two cyclin D-dependent CDKs, CDK4 and CDK6,
induce phosphorylation of the retinoblastoma protein (RB1),
thereby releasing RB1 from its growth inhibitory functions. In
turn, the proteins from the INK4 family inhibit this process and act
as brakes to phase G1 of the cell cycle (Hirama and Koeffler,
1995; Sherr and Roberts, 1995; Sherr, 1996). There are at least
four members of the family, p16INK4A, p15INK4B, p18INK4C
and p19INK4D (to be distinguished from p14ARF). The
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lack of redundancy (Sherr, 1996). The polypeptides are composed
of 4–5 ankyrin repeats, and mutagenesis studies have suggested
that mutations are likely to affect function only if they occur in the
region coding for these ankyrin repeats (Yang et al, 1996). There is
a little information which suggests that the INK4 family members
may have a role in cellular differentiation via effects of the CDKs
on phosphorylation of substrates other than RB; for example, p18
and p19 which are widely expressed during embryogenesis
(Zindy et al, 1997).
All members of the family bind to CDK4 and 6 (Hirai et al,
1995; Guan et al, 1996). They have a moderate degree of
homology. p19INK4D, for example, has 48% amino acid
homology with p16INK4A. All members of the family compete
with cyclin D1 for its binding site on CDKs (Guan et al, 1996).
The presence of each member of the family in phase G1 will
induce G1 arrest, so that at a cellular level at least all members of
the family are potential tumour suppresser genes. We chose p19
INK4D as a candidate gene because of its chromosomal location at
19p13.2, a reported site of repeated translocation in melanoma
tumours (Parmiter et al, 1986).
MATERIALS AND METHODS
DNA from 42 UK families at increased risk of melanoma was
screened for germline mutations. The families have been recruited
in the period since 1989 in England and Wales. Ethical Committee
approval for this study was obtained from all institutions involved.
Twenty-two of these families have been previously described
(Harland et al, 1997). Wherever possible, DNA from two cases
from each family was screened. Six additional US families were
screened for INK4D mutations. These families were selected
because they had sarcoma and/or haematological malignancies
in addition to melanoma. Three of these families have been pre-
viously described (Goldstein et al, 1994; Liu et al, 1997).
DNA extraction and PCR
DNA extraction from peripheral blood, and the polymerase chain
reaction (PCR) amplification of the three coding exons of INK4A,
and exon 2 of CDK4, was carried out as described previously
(Harland et al, 1997).
Analysis of p19 INK4D
Previously, only the cDNA sequence has been available for p19
INK4D (GenBank accession numbers U40343, U20498 and
U49399). Studies using primers designed from this sequence have
been able to cover, at best, 85% of the coding sequence of INK4D
(Shiohara et al, 1996; Miller et al, 1997). In order to examine the
terminal amino acids in each of the two exons of INK4D, and also
the splice donor and acceptor sites, it was important to determine
the intronic sequence of INK4D, so that intronic primers flanking
the two coding exons could be designed. Primers flanking the
cDNA sequence were designed from the available sequence for
the 3¢ and 5¢ non-coding regions (Guan et al, 1996) (GenBank
accession number U40343). Long-range PCR across the two
exons and the intron, in genomic DNA samples, produced a PCR
product approximately 1100 bp longer than would be predicted
from the cDNA sequence. Sequencing through the coding regions
and into the intron has enabled us to determine the complete
intronic sequence of INK4D, 1091 bases in total. This sequence,
which has been submitted to GenBank (accession number
AF061327), has enabled us to design primers flanking the two
exons of p19, and so allowed us to investigate the complete coding
region of p19 INK4D in our families.
Long-range PCR of p19 INK4D
Primers were based on the p19 INK4D cDNA sequence (GenBank
accession number U40343) (Table 1). A total of 100 ml long-range
PCR reactions were carried out using 250 ng genomic DNA,
0.2 mM dNTPs, 50 mM each primer, 10% dimethyl sulphoxide
(DMSO), and 5 units Deep Vent DNA polymerase (New England
Biolabs), in the reaction buffer provided by the supplier. Thermal
cycling conditions were as follows: an initial denaturation at 94°C
for 5 min; followed by 35 cycles of denaturing at 94°C (30),
annealing at 55°C (30), and extension at 72°C (6¢), with a final
10-min extension at 72°C. PCR fragments were isolated by
agarose gel electrophoresis and purified prior to sequencing using
the QIAquick Gel Extraction Kit (Quiagen). Sequencing of the
intronic region was performed as described below, using forward
and reverse primers designed from the known cDNA sequence,
and also primers designed from generated intronic sequence
(Table 1). PCR amplification for the screening of the two exons of
p19 INK4D, was carried out as described previously for INK4A
and CDK4 (Harland et al, 1997), the primers used are shown in
Table 1.
Sequencing
Sequencing reactions were carried out using the ABI PRISM
BigDye Terminator Cycle Sequencing Kit (Perkin-Elmer) and the
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Table 1 p19 INK4D primers used
Primer Sequence Annealing Usage
temp (°C)
p19-N1F GCCAGTGTCGACATGCTG 55 Long-range PCR (F)
Intronic sequencing (F)
PCR amplification, exon 1 (F)
p19-N2R TGTCCAACACACCAAAAGGA 55 Long-range PCR (R)
p19-2R CGGAGGTGTCCTGGACATTG 55 Intronic sequencing (R)
p19-in1F CTGGGAACCGGTCCTTCTCT 55 Intronic sequencing (F)
p19-in1R AGGGGTCACTGGAAAGAGAA 55 Intronic sequencing (R)
p19-ex1R CTGGGAACCGGTCCTTCTCT 55 PCR amplification, exon 1 (R)
p19-143F ACTTTCCTGGGGGCTTATGC 55 PCR amplification, exon 2 (F)
p19+98R CTATAAGCCACAAACTGTGC 55 PCR amplification, exon 2 (R)products were analysed on an ABI 377 DNA sequencer. DNA
sequencing was performed in both directions, initiated from the
forward and reverse primers used in the initial PCR amplification
of each exon. In kindreds where sequence variation was found in
one or both of the initial samples selected for investigation, all
members of that family, for whom DNA was available, were
sequenced for the putative mutation identified in the initial
samples, in order to study the segregation of the mutation with
melanoma.
RESULTS
Table 2 shows the characteristics of the families screened. Forty-
two UK families were mutation tested (Table 3). Partial testing
was reported in 22 of these families previously (Harland et al,
1997). Six additional US families were screened for INK4D
mutations in whom significant INK4A and CDK4 mutations had
previously been excluded (Hussussian et al, 1994). In one of these
families, Asn71Ser was identified. This mutation has not yet been
shown to have functional implications (Ranada et al, 1995). In
total, 26 families with three or more cases, and 22 with only two
cases of melanoma were screened. In nine of the 22 families with
two cases of melanoma, one of those cases had proven multiple
primary tumours, as additional evidence for an underlying genetic
susceptibility to melanoma.
The three UK families not previously reported with germline
mutations had Arg24Pro (in common with another UK family and
several others world-wide), Met53Ile (again in common with a
second UK family and others world-wide) and a novel single base
pair substitution Gly67Arg (Figure 1).
A previously reported polymorphism in exon 1 of INK4D, was
detected in codon 30 (Miller et al, 1997) in cases from five fami-
lies with three or more cases of melanoma and one family with two
cases only. No mutations were identified in either CDK4 exon
2 or the INK4D genes.
DISCUSSION
INK4A (CDKN2) clearly underlies susceptibility to melanoma in a
significant proportion of melanoma-prone families, and germline
mutations in the CDK4 gene underlie susceptibility in a small
minority of families. We report three new families with germline
mutations. Two of these have been widely reported in other
centres, and in all families the mutations co-segregate with the
tumours. Furthermore, functional assays have shown these muta-
tions to be significant (Harland et al, 1997). The novel mutation
Gly67Arg has not, to our knowledge, been reported before, but
it occurs at a site predicted by the ankyrin structure of the p16
protein, to be critical to function. A similar, single base pair
substitution at the same codon has been detected in an Australian
pedigree (Mann et al, 1997).
In this series of 42 UK families recruited since 1989, 36% of
families with three or more cases and 5% of families with only
two cases had identifiable INK4A mutations. The prevalence of
germline INK4A mutations in the larger families is consistent with
that reported world-wide. Some authors have suggested that
approximately 25% of families with two or more cases in
Australia, Europe and the USA have identifiable mutations, and in
a population-based study in Sweden by Platz et al the frequency of
these mutations was estimated to be even lower (Platz et al, 1997).
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Table 2 The family characteristics of those families screened in which there were three or more cases of melanoma. The number of cases
reported is shown, and whether or not the family is known to have had cases with multiple primaries
Pedigree Number Cases with INK4A INK4A INK4A CDK4 INK4D INK4D
number of cases multiple exon 1 exon 2 exon 3 exon 2 exon 1 exon 2
primaries
MEL21 10 Yes Arg24Pro
NIH 1 10 Yes Ala148Thr
MEL07 5 Yes
MEL09 5 Yes Met53lle 90C/G
MEL32 5 Yes Met53lle
MEL48 5 Not known
NIH 2 5 Yes 90C/G
MEL02 4 Not known 90C/G
MEL03 4 No
MEL06 4 Yes
MEL13 4 Yes 23ins24
MEL15 4 Yes Ala118Thr
MEL26 4 Yes
MEL37 4 Not known 90C/G
MEL39 4 Not known Gly67Arg
MEL40 4 Yes Arg24Pro
MEL49 4 Yes 90C/G
MEL24 3 No 88delG
MEL28 3 No
MEL30 3 No
MEL35 3 No 90C/G
MEL44 3 Yes 90C/G
MEL50 3 No 90C/G
MEL53 3 Yes 90C/G
NIH 3 3 Yes Asn71Ser
NIH 4 3 No
Polymorphisms are indicated in italics. The protein produced by mutation Asn71Ser has been normal in vitro testing.The reported studies are difficult to compare, as noted by
Goldstein and Tucker (1997), because different groups have been
variably stringent in their selection criteria. Some stipulate that the
number of cases reported should be in first-degree relatives, others
do not. Furthermore, groups appear to vary in how rigorously they
sought mutations. In this study, there appears to be a clear differ-
ence in the likelihood of identifying germline INK4A mutations in
families of different sizes. Mutations were significantly more
likely in families with larger numbers of cases (Table 4). This
might imply that the families with larger numbers of cases are less
likely to represent clustering of cases by chance alone, or that they
carry more penetrant genes.
Overall, in the families with three or more cases, 64% did not
have identifiable INK4A mutations, nor did they have the rarer
CDK4 exon 2 mutations. There is some evidence from other
groups that some families without detectable INK4A mutations
still have evidence of linkage to chromosome 9 (Walker et al,
1995) and it may be that, in these families, there are still to be
found mutations in intronic sequences or the promoter that have an
effect on p16 transcription.
There is some evidence for linkage to other chromosomes (Bale
et al, 1989; Walker et al, 1994) and we have previously reported
suggestive haplotype data (MacGeoch et al, 1994) so that it also
seems likely that there are other high penetrance melanoma
susceptibility genes to be identified. We have taken a candidate
gene approach to the identification of such genes. It would seem
that the p16/RB1 pathway is of critical importance in melanoma
carcinogenesis and therefore we chose to look at another member
of the INK4 family, p19 INK4D.
The four members of the INK4 family appear to function in a
similar way in terms of binding to CDK4/6 and inducing G1 arrest.
The role of members of the INK4 family, other than INK4A, in
carcinogenesis is not yet clear. Mutations in all four members of
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Table 3 The family characteristics of those families screened in which there were two cases of melanoma. All families have been screened
for exons 1–3 of INK4A, exon 2 of CDK4 and exons 1 and 2 of INK4D. Only positive findings are indicated.
Pedigree Number Cases with INK4A INK4A INK4A CDK4 INK4D INK4D
number of cases multiple exon 1 exon 2 exon 3 exon 2 exon 1 exon 2
primaries
MEL01 2 (1st) Yes
MEL04 2 (2nd) Yes
MEL11 2 (1st) Yes
MEL14 2 (1st) Yes
MEL16 2 (1st) Yes
MEL19 2 (1st) Yes
MEL20 2 (2nd) No
MEL22 2 (1st) Yes
MEL23 2 (1st) Yes
MEL25 2 (2nd) Not known
MEL29 2 (1st) Not known 23ins24
MEL34 2 (1st) No
MEL38 2 (1st) No
MEL41 2 (2nd) No
MEL42 2 (1st) No
MEL43 2 (1st) No
MEL46 2 (1st) No
MEL54 2 (1st) Not known
MEL55 2 (1st) No
MEL56 2 (1st) No
NIH 5 2 (1st) Yes
NIH 6 2 (1st) No
a Figure in brackets denotes the degree of relatedness between affected individuals.
Table 4 A summary of the findings in 48 families. The decreasing likelihood
of identifying a mutation with decreasing numbers of cases is illustrated
Number of Number of Number INK4A Families with
cases in family families mutations found mutations (%)
10 2 1 50
55 2 4 0
41 0 3 3 0
39 2 2 2
22 2 1 5
Figure 1 Pedigree of family in which a germline mutation Gly67Arg was
identified. In all, there were four cases of melanoma. The mutation was















Probandthe family have been sought in cell lines. In one study of 100 cell
lines for example, 35 homozygous deletions and seven intragenic
mutations were detected in INK4A, and 29 lines had homozygous
deletions in INK4B. Germline mutations have been sought both in
the INK4B gene coding for p19 and in p14ARF (whose transcript
is derived in part from an alternative codon reading frame of p16)
but no evidence has yet been found for such mutations in
melanoma families (Fitzgerald et al, 1996; Liu et al, 1997). INK4D
is the most recently described member of the INK4 family and the
gene is on chromosome 19 (19p13). Structural chromosome break-
points are reported in around 4% of short-term melanoma cultures
on 19p (Nelson et al, 1996). The chromosomal location of INK4D
is, however, of most interest because of a report by Parmiter et al
(1986) of a translocation involving chromosome 19 at 19p13 in
three cases of melanoma. In only one line, an ovarian cancer cell
line SKOV3, was there a single base pair deletion in exon 1 of
INK4D (Gemma et al, 1996). In tumour samples, abnormalities
have rarely been reported (Shiohara et al, 1996; Miller et al, 1997).
These studies in cell lines and tumour samples suggest a possible
role for INK4D in some specific tumour types but suggest that
INK4D is not a tumour suppresser gene of such fundamental
importance as INK4A.
In summary, we have not found any significant INK4D muta-
tions in the germline of 48 families with a susceptibility to
melanoma. Its similar function to that of INK4A and its chromo-
somal location at a site of translocations in melanoma patients,
made it a candidate gene for genetic susceptibility to melanoma.
To date we have no evidence for such a role, but it might reason-
ably be argued that if p19 does underlie susceptibility in some
families, these families are likely to be rare and screening of
samples from other continents should also be carried out.
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